Short Sellers Attack PetMed Express d/b/a 1-800-PetMeds With False and Defamatory Report
August 23 2017 - 2:14PM
PetMed Express, Inc. (NASDAQ:PETS) : PetMed Express, Inc. today
issued the following statement in response to market activity in
its common stock.
A false and defamatory “report” was published
today by Aurelius Value. We believe that this “report” was intended
to severely manipulate our stock price downward in support of short
sellers. PetMed Express, Inc. categorically denies the allegations
and its implications. We are in the process of reporting this
manipulation to the appropriate regulators. While the Company
dispenses Tramadol and Gabapentin, which represent less than 1% of
annual revenue, it is done exclusively pursuant to valid
prescriptions from veterinarians for the treatment of animals
only. PetMed Express, Inc. will defend itself vigorously
against these false allegations, and is also reviewing all legal
options at its disposal to hold the author(s) of this article
responsible for the baseless attack which has, as of this press
release, caused its stock to decrease substantially.
Shareholders are cautioned against reacting to the false
statements being made. Our financial statements have been and
are routinely audited; and we reiterate that we stand behind the
integrity of our financial statements and SEC filings.
Founded in 1996, PetMed Express, Inc. is
America’s Largest Pet Pharmacy, delivering prescription and
non-prescription pet medications and other health products for dogs
and cats at competitive prices direct to the consumer through its
1-800-PetMeds toll free number and on the Internet through its
website at
www.1800petmeds.com.
This press release may contain “forward-looking” statements, as
defined in the Private Securities Litigation Reform Act of 1995 or
by the Securities and Exchange Commission, that involve a number of
risks and uncertainties, including the Company’s ability to meet
the objectives included in its business plan. Important
factors that could cause results to differ materially from those
indicated by such “forward-looking” statements are set forth in
Management’s Discussion and Analysis of Financial Condition and
Results of Operations in the PetMed Express Annual Report on Form
10-K for the year ended March 31, 2017. The Company’s future
results may also be impacted by other risk factors listed from time
to time in its SEC filings, including, but not limited to, the
Company's Form 10-Q and its Annual Report on Form 10-K.
For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444.
PetMed Express (NASDAQ:PETS)
Historical Stock Chart
From Mar 2024 to Apr 2024
PetMed Express (NASDAQ:PETS)
Historical Stock Chart
From Apr 2023 to Apr 2024